PATH’s Drug Development program announces positive phase 1 results for its anti-diarrheal drug

PATH's Drug Development program has developed a new medication to treat diarrhea. This new drug treats the diarrheal process to shorten its duration.
Spread the Word
Listed Under

Public Health
Developing World
Drug Development



Nov. 12, 2012 - PRLog -- South San Francisco, CA, PATH’s Drug Development program announced today the completion of two phase 1 clinical studies for iOWH032—its investigational new drug to treat acute secretory diarrhea caused by diseases such as cholera. The studies evaluated the drug’s safety and tolerability and measured the extent and rate of its absorption, distribution, metabolism, and excretion, reporting no serious adverse events. Based on these outcomes, iOWH032 will proceed into the next phase of clinical trials in Bangladesh in early 2013.

The development of iOWH032 is funded by the Bill & Melinda Gates Foundation. Unlike most currently available medications, iOWH032 is designed to treat the diarrheal processes directly by reducing fluid secretion, thus shortening both the duration and severity of the symptoms. If approved, the drug would be used in conjunction with oral rehydration therapy and encourage wider adoption of and compliance with treatment.

“We are excited about this milestone. Diarrheal disease remains the second leading killer of children younger than five in the developing world. While this disease is both preventable and treatable, millions of children across the globe suffer needlessly. We can do better,” said Dr. Ponni Subbiah, global program leader for PATH’s Drug Development group. “iOWH032 has potential to be the first synthetic drug of its kind designed to reduce fluid loss and more quickly relieve diarrhea symptoms. We are thankful for the expertise and support of our advisors and partners in the United States and Bangladesh, and look forward to the next phase of development.”

About PATH’s Drug Development global program

PATH’s Drug Development global program was established through our affiliation with OneWorld Health, a nonprofit drug development organization. The program works to develop and ensure availability and accessibility of safe and effective new medicines for diseases disproportionately affecting people in developing countries. For more information, please visit

About PATH

PATH is an international nonprofit organization that transforms global health through innovation. PATH takes an entrepreneurial approach to developing and delivering high-impact, low-cost solutions, from lifesaving vaccines and devices to collaborative programs with communities. Through its work in more than 70 countries, PATH and its partners empower people to achieve their full potential. For more information, please visit
Source:PATH OneWorld Health
Email:*** Email Verified
Tags:Diarrhea, Public Health, Developing World, Drug Development, Medicine
Location:United States
Account Email Address Verified     Disclaimer     Report Abuse
One World Health PRs
Trending News
Top Daily News
Top Weekly News

Like PRLog?
Click to Share